SPAC deal

EQRx’s ambitious plan to sell cheap drugs falls apart after $4.2B deal

EQRx’s ambitious plan to sell cheap drugs falls apart after $4.2B deal

Anika Sharma

EQRx, a biotech company founded with the ambitious mission of developing affordable medicines, recently found itself embroiled in a complex ...